Fortrea sees higher evidence bar for oncology drug development

• Fortrea's ESMO 2026 analysis highlights rising evidence standards in oncology, with survival benefits and stronger comparators increasingly driving competitive differentiation.
• Antibody-drug conjugate competition is intensifying, making patient selection, treatment sequencing and toxicity management critical to differentiation.
• Biomarker-led development requires earlier investment in testing and screening; personalized therapies add manufacturing and delivery challenges.
• China-generated trial evidence is increasingly central to global strategy, requiring prospective planning for differences in populations and standards of care.
• Treatment de-escalation remains unproven: MOIO stopped early following an overall survival imbalance favoring standard dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortrea Holdings Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.